EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Start Date
4/1/2025
Completion Date
9/1/2030
Summary
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay
Detailed Description
The goal of this research study is to evaluate the feasibility of a novel EGFR blood plasma ctDNA screening test among East Asian and Latinx participants at risk for lung cancer and ineligible for regular lung cancer screening. The test looks for a gene change called Epidermal Growth Factor Receptor (EGFR), specifically EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. This study seeks to determine if it is possible to use the blood test to detect this type of lung cancer that might not yet show symptoms. The research study procedures include screening for eligibility, in-clinic visits, blood tests, and an optional questionnaire and/or focus group. It is expected that about 1000 people will participate in the blood sample collection, 100 individuals in the survey, and 20 individuals in the focus groups.
Eligibility Criteria
Age Range: 40 years to 80 years
Interventions
Circulating Tumor DNA (ctDNA) Assay
Conditions
Locations
Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215
United States
Dana-Farber Cancer Institute
Boston, Massachusetts 02215
United States
Massachusetts General Hospital
Boston, Massachusetts 02215
United States
Dana-Farber Cancer Institute at Steward St. Elizabeth's
Brighton, Massachusetts 02135
United States
Dana-Farber Cancer Instiute Merrimack Valley
Methuen, Massachusetts 01844
United States
Dana-Farber Cancer Institute South Shore
South Weymouth, Massachusetts 02190
United States